Trial · NCT02252263
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
NCT02252263, Phase 1, Completed, Bristol-Myers Squibb
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma. Trials, record NCT02252263. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02252263
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
- NCT number
- NCT02252263
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 44 participants, actual
- Lead sponsor
- Bristol-Myers Squibb
- Conditions
- Multiple Myeloma
- Interventions
- Elotuzumab, Lirilumab, Urelumab
- First posted
- 2014-09-30
- Last updated
- 2017-11-01
Source ClinicalTrials.gov
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety as measured by the rate of AEs, SAEs, deaths is the primary endpoint of this Phase 1 study. All subjects who receive at least one (full or partial) dose of Elotuzumab, Lirilumab or Urelumab will be evaluated for safety | During treatment and first 100 days after treatment | adverse events (AEs), serious adverse events (SAEs) |
| Secondary | Best Overall Response (BOR) | At different timepoints approximately up to 2.5 years | |
| Secondary | Objective Response rate (ORR) | At different timepoints approximately up to 2.5 years | |
| Secondary | Median Duration of Response (mDOR) | At different timepoints approximately up to 2.5 years | |
| Secondary | Median Time to Response (mTTR) | At different timepoints approximately up to 2.5 years | |
| Secondary | Progression-free survival rate (PFSR) | At different timepoints approximately up to 2.5 years | |
| Secondary | M-protein levels | At different timepoints approximately up to 2.5 years | |
| Secondary | Minimal Residual Disease (MRD) status for Post Autologous Transplant subjects | At different timepoints approximately up to 2.5 years | |
| Secondary | Maximum concentration of Urelumab (Cmax) | At different timepoints approximately up to 2.5 years | |
| Secondary | Maximum concentration of Lirilumab (Cmax) | At different timepoints approximately up to 2.5 years |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02252263
GET https://conductscience.org/api/trials/v1/NCT02252263/registered?page=2